Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Plastic and Reconstructive Surgery. Global Open|November 2, 2020
The Modified Crescenteric Anterior Intercostal Perforator FlapMax Denning, Philippa Hayes, Fiona Tsang, et al.
Diabetes, Obesity & Metabolism|June 24, 2026
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical TrialsSean Wharton, Adam Stefanski, Jiaxun Chen, et al.
Systematic Reviews|July 4, 2019
Assessing trauma care health systems in low- and middle-income countries, a protocol for a systematic literature review and narrative synthesisJohn Whitaker, Max Denning, Nollaig O'Donohoe, et al.
BMJ Global Health|May 12, 2021
Assessing trauma care systems in low-income and middle-income countries: a systematic review and evidence synthesis mapping the Three Delays framework to injury health system assessmentsJohn Whitaker, Nollaig O'Donohoe, Max Denning, et al.
Lancet (London, England)|March 1, 2026
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialJulio Rosenstock, Daisuke Yabe, David Cox, et al.
Postgraduate Medical Journal|May 27, 2019
Why are patients not more involved in their own safety? A questionnaire-based survey in a multi-ethnic North London hospital populationWai Yoong, Zouina Assassi, Iman Ahmedani, et al.
Obesity (Silver Spring, Md.)|November 4, 2025
People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide TreatmentXuan Li, Dachuang Cao, Helene Sapin, et al.
Diabetes, Obesity & Metabolism|August 19, 2025
Understanding the clinical characteristics associated with health care costs and cost savings upon weight reduction in individuals with obesity or overweightXuan Li, Carlos Vallarino, Max Denning, et al.
JAMA|June 7, 2026
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical TrialFrancesco Giorgino, Sherwin D'Souza, Lisa Ludwig, et al.
Lancet (London, England)|June 8, 2026
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trialMichelle Welch, Thomas Forst, Weiping Jia, et al.
Pageof 2